A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines

The dataset includes data collected at the Division of Pancreatic Surgery of San Raffaele Scientific Institute, Milan, Italy and at HPB Disease Unit of Karolinska Hospital in Stockholm, Sweden.
Demographics, symptoms, clinical history, diagnostic work-up (including laboratory, radiologic and endoscopic data), type of surgery, and pathology data were prospectively collected. All patients were preoperatively discussed in conference [14] . High-risk stigmata (HRS) and worrisome features (WF) of IG and absolute indications (AI) and relative indications (RI) of EG were retrospectively applied. HRS include jaundice, solid mass, main pancreatic duct (MPD) ≥10 mm, enhancing nodules ≥5 mm and cytology positive for high-grade dysplasia or adeno- carcinoma. WF include cyst size ≥30 mm, MPD size of 5–9 mm, pancreatitis, enhancing mural nodule < 5 mm, thickened/enhancing cyst walls, abrupt change in MPD caliber, lymphadenopathy, serum levels of CA 19.9 > 37 U/mL and cyst growth rate > 5 mm/2 years. AI include jaundice, MPD ≥10 mm, enhancing nodules ≥5 mm, solid mass and cytology positive for high-grade dysplasia or adenocar- cinoma. RI include cyst size ≥40 mm, MPD size of 5–9.9 mm, pan- creatitis, enhancing mural nodule < 5 mm, serum levels of CA-19.9 > 37 U/mL, new onset of diabetes and cyst growth rate > 5 mm/year.